These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8728343)

  • 1. Nonparametric expectation maximization population modeling of ganciclovir.
    Preston SL; Drusano GL
    J Clin Pharmacol; 1996 Apr; 36(4):301-10. PubMed ID: 8728343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.
    Zhou XJ; Gruber W; Demmler G; Jacobs R; Reuman P; Adler S; Shelton M; Pass R; Britt B; Trang JM; Whitley RJ; Sommadossi JP
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2202-5. PubMed ID: 8878608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
    Welker H; Farhan M; Humar A; Washington C
    Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study.
    Mouly S; Aymard G; Tillement JP; Caulin C; Bergmann JF; Urien S
    Br J Clin Pharmacol; 2001 Jun; 51(6):557-65. PubMed ID: 11422015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN.
    Padullés Caldés A; Colom H; Caldes A; Cerezo G; Torras J; Grinyó JM; Lloberas N
    Ther Drug Monit; 2014 Jun; 36(3):371-7. PubMed ID: 24305626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
    Yuen GJ; Drusano GL; Fletcher C; Capparelli E; Connor JD; Lalezari JP; Drew L; Follansbee S; Busch D; Jacobson M
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2350-2. PubMed ID: 8619596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm--a retrospective study.
    Terziivanov D; Atanasova I; Dimitrova V
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):376-82. PubMed ID: 9707352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F; Banken L; Saywell K; Arum I
    Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
    Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection.
    Dong Q; Leroux S; Shi HY; Xu HY; Kou C; Khan MW; Jacqz-Aigrain E; Zhao W
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
    Jung D; AbdelHameed MH; Teitelbaum P; Dorr A; Griffy K
    J Clin Pharmacol; 1999 May; 39(5):505-12. PubMed ID: 10234599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates.
    de Hoog M; Schoemaker RC; van den Anker JN; Vinks AA
    Ther Drug Monit; 2002 Jun; 24(3):359-65. PubMed ID: 12021626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.
    Trang JM; Kidd L; Gruber W; Storch G; Demmler G; Jacobs R; Dankner W; Starr S; Pass R; Stagno S
    Clin Pharmacol Ther; 1993 Jan; 53(1):15-21. PubMed ID: 8380762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration.
    Morlet N; Young S; Naidoo D; Graham G; Coroneo MT
    Br J Ophthalmol; 1996 Mar; 80(3):214-6. PubMed ID: 8703858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
    Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
    N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.
    Spector SA; Busch DF; Follansbee S; Squires K; Lalezari JP; Jacobson MA; Connor JD; Jung D; Shadman A; Mastre B
    J Infect Dis; 1995 Jun; 171(6):1431-7. PubMed ID: 7769276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.